Cescon: #AACR17 Their last compound - CX-5461, a G-quadruplex DNA stabilizer. '17 ref https://t.co/ENWd6mri3q
4:06pm April 3rd 2017 via Hootsuite
Cescon: #AACR17 TTK kinase inhibitor - '17 PNAS https://t.co/TUzPKVjCWT Multi-site Ph I underway. Next year Ph II planned.
4:02pm April 3rd 2017 via Hootsuite
Cescon: Targeting aneuploidy with TKIs - centriole duplication and spindle formation. https://t.co/3dRPvE7MKd #AACR17
3:56pm April 3rd 2017 via Hootsuite
Cescon: Describes 3 novel therapeutics; PLK4 and TTK as targets (polo-like kinase, TTK for spindle assembly) #AACR17
3:55pm April 3rd 2017 via Hootsuite
Cescon: Aggressive breast cancers - poor outcomes, short survival. Genomically unstable, HR-mediated DNA repair #AACR17
3:50pm April 3rd 2017 via Hootsuite
David Cescon (Princess Margaret CAN) Novel agent targeting breast cancer vulnerabilities #AACR17
3:49pm April 3rd 2017 via Hootsuite
Arrowsmith: Their group - epigenetic chemical probe screening results, targeting stem cell compartment #AACR17
3:42pm April 3rd 2017 via Hootsuite
Arrowsmith: For metabolomics - a group ID'd a new metabolite 'same mass as isocitrate but it is not isocitrate' (to be ID'd). AACR17
3:40pm April 3rd 2017 via Hootsuite
Arrowsmith: Shows list of top 20 mutated genes in GBM from TCGA cp to their samples. Lupien's group uses ATAC-Seq for active chr #AACR17
3:38pm April 3rd 2017 via Hootsuite
Arrowsmith: #AACR17 Data from Dirks and Lupien labs (submitted) show ASCL1 high level expression show latent differentiation
3:36pm April 3rd 2017 via Hootsuite
Arrowsmith: Use multi-omics to generate data; go through drug sens screening, better inform clinical trials #AACR17
3:34pm April 3rd 2017 via Hootsuite
Arrowsmith: Serum-free culture brain tumor cells with high percentage of stem cells; derive models to characterize #AACR17
3:31pm April 3rd 2017 via Hootsuite
Arrowsmith: Brain cancer 'is a disease of aberrant stemness'. Rx targeting based on genomic data - failed in malignant brain tumors #AACR17
C Arrowsmith: Targeting brain tumor stem cell epigenetic and molecular networks #AACR17
3:30pm April 3rd 2017 via Hootsuite
Q: Are the number of cells large enough? Garnett: Can grow 30-50 cryovials; a 'very large number of cells' #AACR17
3:28pm April 3rd 2017 via Hootsuite
Q: Has heterogeneity been proven? Mutation by error in division? Garnett: No obvious pattern of accumulation in-vitro #AACR17
3:26pm April 3rd 2017 via Hootsuite
Garnett: Done afatinib dose-response with combinations. With Taselisib, shows potent synergy; IC50 shifted, and cell killing #AACR17
3:23pm April 3rd 2017 via Hootsuite
Garnett: Drug sensitivity assay in organoid ref '16 https://t.co/c93b14K7wo #AACR17
3:22pm April 3rd 2017 via Hootsuite
Garnett: Organoid data suggests untreated samples have pre-existing phenotypic diversity. Developed a method for quick dose-response #AACR17
3:20pm April 3rd 2017 via Hootsuite
Garnett: Limited drug testing data shown; from dozends to >100 cultures as part of their organoid biobank. https://t.co/Cr1aAcDss5 #AACR
3:15pm April 3rd 2017 via Hootsuite
Garnett: Total mutational burden and signature; closely conserved between tissue and organoid (about 20 shown), wide diversity #AACR17
3:12pm April 3rd 2017 via Hootsuite
Garnett: Shows brast tissue (ductal carcinoma) and copy-number alterations, Tissue / organoid compares favorably. #AACR17
3:11pm April 3rd 2017 via Hootsuite
Garnett: #AACR17 (NB - here's a '16 Cell review on organoids https://t.co/49z6V2z5RV )
3:10pm April 3rd 2017 via Hootsuite
Garnett: Work via Sachs, Clevers: breast cancer organoids, can grow >20 passages in vitro. To date - 70% success rate #AACR17
3:09pm April 3rd 2017 via Hootsuite
Garnett: Organoids are a 3D model - high success rate. Thus we can get models that exhibit diversity. Diverse technology #AACR17
3:07pm April 3rd 2017 via Hootsuite
Garnett: Existing models do not encompass intra- and inter-pt heterogeneity. PDX are state-of-the-art, but slow, costly, specialized #AACR17
Garnett: A real need for better models, accelerate the rate of precision medicine. Most effective - small subsets of pts, #AACR17
3:06pm April 3rd 2017 via Hootsuite
Garnett: Stratification of pts has shown immense benefit for some; majority is conventional chemo. Only 10% have actionable mut's #AACR17
3:05pm April 3rd 2017 via Hootsuite
Sharp: 5 teams today, set for 20' apiece. #AACR17 Matthew Garnett (Wellcome Trust) Modeling tumor heterogeneity and drug resp in organoids
3:04pm April 3rd 2017 via Hootsuite
Sharp: #AACR17 This one on precision medicine; earlier session held today about immunotherapy. $36M spec for prec med teams to ID pts
3:03pm April 3rd 2017 via Hootsuite
Phil Sharp (MIT) Genomics and Beyond at #AACR17 - 19 dream teams, $148M raised; 6 translational teams; 36 innovation grants. @SU2C
3:02pm April 3rd 2017 via Hootsuite
If you are looking for ctDNA reference material, check out @Seracare poster 2738 in Section 30 from 1-4pm at #AACR17
1:01pm April 3rd 2017 via Hootsuite
Rimm: Most of heterogeneity captured in a single slide. Compared PD-L1 via MS: good correlation (but lots of tissue needed) #AACR17
11:46am April 3rd 2017 via Hootsuite
Rimm: People like things in bins. https://t.co/7rP8IVidLG And quantitation experiment '16 ref https://t.co/8oqJ1wDfgT #AACR17
11:45am April 3rd 2017 via Hootsuite
Rimm: The NCCN/BMS study: https://t.co/I0ii3QdI17 Brings up the limitations of 2D vs. 3D imaging w/absorptive, emissive #AACR17
11:42am April 3rd 2017 via Hootsuite
Rimm: 13 pathologists reading the NCCN/BMS study - only 28-8 andd E1L3N are statistically same. Rest: statistically sig different #AACR17
11:39am April 3rd 2017 via Hootsuite
Rimm: How compared - split at pos/neg cut-points for each test. Only 63% concordance between 4 assays. 37% non-concordance! #AACR17
11:37am April 3rd 2017 via Hootsuite
Rimm: NCCN study - n=90. Looking at different recipes; across 4 Abs. SP142 enhanced for immune cells (?) NCCN similar SP142 #AACR17
11:36am April 3rd 2017 via Hootsuite
Rimm: The Antibody is the Egg; the Assay is the Cake. Blueprint study N=39 ref https://t.co/5mw6evzcjS #AACR17
11:35am April 3rd 2017 via Hootsuite
Rimm: SP142 is also complementary for bladder, lung ca scoring. E1L3N is used as LDT at MSKCC and BWH. "Are they equivalent?" #AACR17
11:32am April 3rd 2017 via Hootsuite
Rimm: Only Dako 22c3 assay is FDA approved as a CDx; >50% tumor cells positive. Dako 28-8 is 'complementary' for >1% tumor cells #AACR
11:31am April 3rd 2017 via Hootsuite
Rimm: Lower PD-L1 have lower response. Each response 'different cutoffs' '16 review https://t.co/o4R34ls7sX #AACR17
11:30am April 3rd 2017 via Hootsuite
David Rimm (Yale CT) PD-L1 based predictive factors as companion diagnostics for immunotherapy #AACR17
11:28am April 3rd 2017 via Hootsuite
Taube: CD8, FoxP3, CD68, Sox10... for additional markers to look at #AACR17
11:27am April 3rd 2017 via Hootsuite
Taube: Using imaging of PD-L1, PD-1, different radii. Conclude: combining PD-L1 w/IFNg and PD-1 promising. Want multiplex IHC #AACR17
11:26am April 3rd 2017 via Hootsuite
Taube: Group at GenOptix presented AACR16, comparing PD-1/PD-L1 interaction score to PD-L1 IHC #AACR17
11:22am April 3rd 2017 via Hootsuite
Taube: Pretreated PD-L1+, IFN-g+ NSCLC may benefit from decrease in tumor size (ASCO poster) #AACR17
11:21am April 3rd 2017 via Hootsuite
Taube: Shows patterns of PD-L1 in SCC cp to non-squamous in lung. https://t.co/jOEP7XRt1n TCGA https://t.co/cpcJKFCK4h #AACR17
11:20am April 3rd 2017 via Hootsuite
Taube: PD-L1+ w/TIL: responsive to immunotherapy. For PD-L1-, no TILs use combination Rx. https://t.co/yp82cEZOqK #AACR17
11:15am April 3rd 2017 via Hootsuite
Taube: Constitutive, +adaptive, 4 patterns: 'not all PD-L1 is created equal' '16 ref https://t.co/dO7o4tMXmT #AACR17
11:12am April 3rd 2017 via Hootsuite
